Dincer N, Balci S, Yazgan A, Guney G, Ersoy R, Cakir B, Guler G
Departments of PathologyEndocrinology and Metabolism, Yildirim Beyazit University, Ankara Ataturk Research and Education Hospital, Ankara, Turkey.
Cytopathology. 2013 Dec;24(6):385-90. doi: 10.1111/cyt.12021. Epub 2012 Oct 18.
To report our experience of atypia of undetermined significance (AUS)/follicular lesion of undetermined significance (FLUS) rate and outcome.
Among 7658 patients with 19 569 nodules, 524 (2.7%) nodules were diagnosed as AUS/FLUS on fine needle aspiration (FNA). After exclusion of patients with simultaneous nodules that were suspicious for follicular neoplasm or malignancy or that were malignant, 368 (4.8%) patients were diagnosed as AUS/FLUS. The outcome of 146 patients who had undergone surgery or repeated fine needle aspirate at the time of preparation of this study was evaluated. The original FNAs were matched to repeated FNAs and thyroidectomy or diagnostic lobectomy specimens.
Seventy-two (19.6%) of the 368 patients had directly undergone surgery, either a lobectomy or a thyroidectomy: of these, 27 (37.5%) had neoplastic nodules (21 were malignant). Seventy-four (20.1%) of the 368 patients had repeat FNA. On second FNA, 47 of 74 (63.5%) were benign, three were suspicious for follicular neoplasm, one was malignant and 23 (31.1%) were non-diagnostic. Four patients had a third FNA: two were AUS/FLUS, one was malignant and one non-diagnostic. One patient had a fourth FNA, which was diagnosed as AUS/FLUS. Sixteen (21.6%) of 74 patients with repeat FNA had surgery: three of these had neoplastic nodules (two were malignant). Overall, 88 of the 368 (23.9%) patients had a thyroidectomy of which 30 (34.1%) were neoplastic and 23 (26.1%) malignant. The neoplastic rate for patients who were once diagnosed with AUS/FLUS was 8.2% and the malignancy rate 6.3%. The malignancy rate for patients on follow-up at the time we prepared the study was 15.7% (23/146); 222 remained on follow-up without surgery or repeat FNA or were managed elsewhere.
Although in this category repeat FNA is expected rather than excision, we suggest evaluation of all AUS/FLUS patients in multidisciplinary meetings to decide management and recommend follow-up of all patients with this diagnosis.
报告我们在意义不明确的非典型性病变(AUS)/意义不明确的滤泡性病变(FLUS)发生率及转归方面的经验。
在7658例有19569个结节的患者中,524个(2.7%)结节在细针穿刺抽吸活检(FNA)时被诊断为AUS/FLUS。排除同时存在可疑滤泡性肿瘤或恶性肿瘤或恶性结节的患者后,368例(4.8%)患者被诊断为AUS/FLUS。对本研究准备时已接受手术或重复细针穿刺抽吸活检的146例患者的转归进行评估。将最初的FNA结果与重复FNA结果以及甲状腺切除术或诊断性叶切除术标本进行匹配。
368例患者中有72例(19.6%)直接接受了手术,即叶切除术或甲状腺切除术:其中27例(37.5%)有肿瘤性结节(21例为恶性)。368例患者中有74例(20.1%)接受了重复FNA。在第二次FNA时,74例中有47例(63.5%)为良性,3例可疑为滤泡性肿瘤,1例为恶性,23例(31.1%)诊断不明确。4例患者进行了第三次FNA:2例为AUS/FLUS,1例为恶性,1例诊断不明确。1例患者进行了第四次FNA,诊断为AUS/FLUS。74例接受重复FNA的患者中有16例(21.6%)接受了手术:其中3例有肿瘤性结节(2例为恶性)。总体而言,368例患者中有88例(23.9%)接受了甲状腺切除术,其中30例(34.1%)有肿瘤性病变,23例(26.1%)为恶性。曾被诊断为AUS/FLUS的患者肿瘤发生率为8.2%,恶性率为6.3%。在我们准备本研究时,接受随访的患者恶性率为15.7%(23/146);222例患者仍在接受随访,未进行手术、重复FNA或在其他地方接受治疗。
虽然对于此类情况预期进行重复FNA而非切除,但我们建议在多学科会议上对所有AUS/FLUS患者进行评估以决定治疗方案,并建议对所有诊断为此类的患者进行随访。